Petrelintide for Type 2 Diabetes

(ZUPREME-4 Trial)

This trial tests a new treatment called petrelintide to evaluate its effectiveness in helping people with Type 2 Diabetes (T2D) manage their weight. Participants will receive either petrelintide or a placebo, alongside a reduced-calorie diet and increased physical activity. The trial aims to determine if petrelintide is safe and effective for individuals with T2D who are overweight or obese. This trial may suit those diagnosed with T2D, having a BMI of 27 or higher, and who have struggled to lose weight through dieting. As a Phase 3 trial, it represents the final step before FDA approval, offering a chance to contribute to a potentially groundbreaking treatment for T2D.

Research has shown that petrelintide is generally safe and well-tolerated. In one study, only 1.9% of participants stopped treatment due to side effects, mainly related to stomach issues. Other studies have found that petrelintide did not cause serious side effects. Some mild side effects were reported, but they were not severe. Petrelintide's safety was similar to that of a placebo, which contains no active drug. Overall, current data suggests that petrelintide has a good safety profile.¹²³⁴⁵

Unlike the standard treatments for type 2 diabetes that typically focus on controlling blood sugar through mechanisms like insulin regulation or glucose absorption, Petrelintide offers a fresh approach by potentially mimicking the effects of naturally occurring hormones that regulate appetite and blood sugar. This new mechanism of action could provide better control over blood glucose levels and help in weight management, a significant challenge for many with type 2 diabetes. Researchers are excited about Petrelintide because it targets both blood sugar and weight, offering a comprehensive treatment option that could improve overall disease management.

In this trial, participants will receive either petrelintide or a placebo. Studies have shown that petrelintide can help people with type 2 diabetes lose weight. In earlier trials, participants lost an average of up to 9.2% of their body weight over 28 weeks. Another study found even more weight loss, about 10.7%. These results suggest that petrelintide might be effective for weight management in those with type 2 diabetes. This treatment mimics a hormone called amylin, which helps control hunger and food intake. Overall, the evidence supports petrelintide as a promising option for managing weight in people with type 2 diabetes.⁶⁷⁸⁹¹⁰